Not Signed In - Study Showed Epratuzumab In Combination With Rituximab And Chemotherapy Is Safe, Tolerable, And Active In Aggressive Lymphoma
Tue, 05 Dec 2006 08:00 AM EST
... Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today reported that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) produced promising results. [click link for full article] ...
Related Topics
- Non-Hodgkin's Lymphoma
- Chemotherapy
- Hodgkin's Lymphoma
- Rituximab
- Lymphoma
- Burkitt's Lymphoma
- Lymphoma, Burkitt's
- Safe Motherhood
- Combination Vaccines
- Side effects of chemotherapy (depending on the type of chemotherapy)
- Aggressive Behavior
- Fluorouracil
- Passive-aggressive personality disorder
- Combination Diet
- Chronic active hepatitis
- Adult Hodgkin's Lymphoma
- Hodgkin's Lymphoma, Adult
- Adult Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma, Adult
- Safe Blood Handling
email this page
print this page
bookmark this page
feedback on this page
